PDCD1 and head and neck squamous cell carcinoma: Here, we describe a multi-pronged strategy to interrogate the response dynamics of the PD-1 checkpoint inhibitor, nivolumab, using our ex vivo system with human head and neck squamous cell carcinoma (HNSCC) biopsies (N = 50) where actual clinical response is unknown.